CICarlos Emilio Insfran

Carlos Emilio Insfran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carlos Emilio Insfran has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety and effectiveness of rituximab biosimilar (Rituximab-GP2013) versus originator in rheumatoid arthritis: real-world evidence from a single center

    by Barbara Bayeh, Fanny Reyes-Neira, Karina Rossi Bonfiglioli, Nadia Emi Aikawa, Ana Paula Luppino Assad, Renata Miossi, Fernando Henrique Carlos de Souza, Carlos Emilio Insfran, Henrique Ayres Mayrink Giardini, Emily Figueiredo Neves Yuki, et al.

  • Doenças reumatológicas que mimetizam o câncer: doença de Still, vasculites associadas ao ANCA, doença relacionada à IgG4 e sarcoidose

    by Mariana Freitas de Aguiar, Erika Biegelmeyer, Henrique Ayres Mayrink Giardini, Carlos Emílio Insfran Echauri

    As doenças reumatológicas sistêmicas podem apresentar fenótipos clínicos e radiológicos que mimetizam neoplasias, representando um desafio diagnóstico relevante e potencialmente associado a atraso terapêutico, exposição a procedimentos invasivos e terapias inadequadas. Entre essas condições, a doença de Still, as vasculites associadas ao ANCA, a doença relacionada à IgG4 (DR-IgG4) e a sarcoidose, cujas apresentações pseudoneoplásicas decorrem de mecanismos fisiopatológicos distintos, frequentemente convergem para manifestações semelhantes, como febre, perda ponderal, linfadenopatias, massas expansivas, lesões infiltrativas e hipercaptação ao PET/CT com 18F-FDG. Na doença de Still, quadros inflamatórios sistêmicos exuberantes, hiperferritinemia e linfadenomegalias podem simular neoplasias hematológicas, especialmente linfomas. Nas vasculites associadas ao ANCA, granulomas necrosantes e lesões pseudotumorais podem acometer múltiplos órgãos, reproduzindo padrões radiológicos e histológicos indistinguíveis de tumores sólidos ou doenças linfoproliferativas. Na DR-IgG4, o padrão fibroinflamatório tumefativo, frequentemente multissistêmico, constitui importante diagnóstico diferencial de neoplasias. Já a sarcoidose sistêmica, que representa um modelo complexo de interface entre inflamação granulomatosa e câncer, pode mimetizar malignidade, coexistir com neoplasias ou manifestar-se como uma reação secundária ao tumor. Nesses cenários, a diferenciação diagnóstica exige abordagem integrada, baseada na correlação entre fenótipo clínico, biomarcadores, achados de imagem e estudo histopatológico dirigido.

  • Open Access

    Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study

    by Fanny Alcira Reyes Neira, Barbara Bayeh, Karina Rossi Bonfiglioli, Nadia Emi Aikawa, Ana Paula Luppino Assad, Renata Miossi, Fernando Henrique Carlos de Souza, Carlos Emilio Insfrán, Henrique Ayres Mayrink Giardini, Emily Figueiredo Vieira Neves Yuki, et al.

    Aim: The use of anti-TNF drugs is well-established for treating axial spondyloarthritis (axSpA). The introduction of biosimilars offers a more accessible alternative, but data on the switching of adalimumab biosimilars in the axSpA population remain somewhat controversial and are limited to SB5 and ABP 501 and to the European population. This study aims to evaluate the clinical efficacy of switching from originator adalimumab to the biosimilar adalimumab-AACF in Latin American axSpA patients over a 12-month period in a real-life analysis. Methods: This observational study included patients with axSpA who had been treated with originator adalimumab for at least three months and switched to the biosimilar. Disease activity parameters and C-reactive protein (CRP) levels were assessed at baseline (T0) and compared at 6 (T6) and 12 months (T12) following the switch. Results: Twenty-eight patients were included, with a mean duration of originator adalimumab use of 87.6 months. Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP remained stable when comparing T0 to T6 [1.56 (± 0.88) vs. 1.50 (± 0.82), P = 0.73] and T12 [1.56 (± 0.88) vs. 1.26 (± 0.86), P = 0.13]. A similar pattern was observed for ASDAS-erythrocyte sedimentation rate (ESR; P > 0.05) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI; P > 0.05). The rate of remission/low disease activity was consistent, recorded at 71.4% at baseline, 78.6% at T6 (P = 0.62) and 78.6% at T12 (P = 0.68). CRP levels did not show significant variation (P > 0.05) across time points. Notably, the one-year drug retention rate was 94.6%. Conclusions: This real-world study highlights for the first time the feasibility and efficacy of transitioning from originator adalimumab to biosimilar AACF in axSpA, providing support for its use in long-term management and offering enhanced accessibility without compromising therapeutic outcomes. These results add valuable Latin American data to the body of evidence on biosimilar integration into clinical practice.